Wedbush Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $141

Benzinga · 07/31/2025 13:14
Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $137 to $141.